SOFIE has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan, as its latest site in SOFIE’s sponsored clinical trial, “A Phase 2, Multicenter, Single- Arm, Open-Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients with resectable or borderline resectable Pancreatic Ductal Carcinoma (PDAC) NCT05262855.”
BAMF Health began treating metastatic prostate cancer and neuroendocrine tumor (NET) patients in August 2022. Their advanced radiopharmacy and clinical infrastructure were designed as a platform to serve companies like SOFIE and their patients by manufacturing radiopharmaceuticals and conducting clinical trials for a wide variety of diseases.
“It has been a pleasure to combine our expertise with BAMF’s for the launch of this trial in Michigan,” said Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer. “BAMF’s purpose-built clinical trials platform enables rapid technology transfer for radiopharmaceutical manufacturing, efficient study startup, and high quality of data simultaneously, which allows us to focus on our mission.”
BAMF joins NYU Langone, Mayo Clinic, and UCLA as the four clinical sites for [68Ga]FAPI-46, following initiation of the study in May 2022.
